Guggenheim raises target for Elevance Health stock to USD 460

Published on 10/14/2026 at 12:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elevance Health stock faces USD 49.29 billion for the third quarter. It costs EUR 381.40 on October 14, 2026.

Targets and results dates

Guggenheim lifted its target to USD 460 on October 12, 2026.
Second-quarter operating revenue reached USD 49.83 billion on July 15, 2026.
Elevance Health stock was trading at EUR 381.40 at 12:14 p.m. CEST on October 14, 2026.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Guggenheim raised its Elevance Health price target from USD 455.00 to USD 460.00 on October 12, 2026, while keeping a Buy rating, according to Investing.com. The target revision puts the upcoming third-quarter report at the center of the stock story.

Guggenheim sees earnings recovery

Guggenheim cited improved performance across Elevance Health's Medicaid, Medicare Advantage and Individual ACA businesses. The firm also pointed to the company's diversified earnings base, pricing actions and cost initiatives as support for an earnings recovery, according to Investing.com.

The same report said Guggenheim was targeting adjusted earnings per share growth of more than 12 percent in 2027 and beyond. That expectation contrasts with the near-term earnings hurdle, because MarketBeat listed consensus estimates of USD 4.70 earnings per share and USD 49.29 billion in revenue for the third quarter.

Three dated signals before results

On July 15, 2026, Elevance Health reported second-quarter operating revenue of USD 49.83 billion and adjusted diluted earnings per share of USD 7.45, according to Drillr. On October 5, 2026, the company scheduled its third-quarter release for 6:00 a.m. EDT on October 21, 2026, according to its Elevance Health release. Guggenheim's USD 460.00 target followed on October 12, 2026.

What will the report test?

The October 21 report will test whether the better performance cited by Guggenheim translates into the USD 49.29 billion revenue estimate and USD 4.70 earnings-per-share consensus. Elevance Health's latest reported quarter delivered USD 49.83 billion in operating revenue, but the next report will show whether that scale can be maintained alongside medical-cost pressure and Medicaid restructuring.

Stock price and reporting date

Elevance Health was trading at EUR 381.40 at Lang & Schwarz on October 14, 2026 at 12:14 p.m. CEST. Finance data put the company's market capitalization at USD 92.2 billion as of October 13, 2026, while its primary listing is NYSE under ticker ELV. The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.